ATE258434T1 - Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält - Google Patents

Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält

Info

Publication number
ATE258434T1
ATE258434T1 AT94922555T AT94922555T ATE258434T1 AT E258434 T1 ATE258434 T1 AT E258434T1 AT 94922555 T AT94922555 T AT 94922555T AT 94922555 T AT94922555 T AT 94922555T AT E258434 T1 ATE258434 T1 AT E258434T1
Authority
AT
Austria
Prior art keywords
agents
self
delivery system
system containing
polynucleotide delivery
Prior art date
Application number
AT94922555T
Other languages
English (en)
Inventor
Francis C Szoka Jr
Jean Haensler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22232131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE258434(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE258434T1 publication Critical patent/ATE258434T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
AT94922555T 1993-07-14 1994-07-14 Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält ATE258434T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9220093A 1993-07-14 1993-07-14
PCT/US1994/007916 WO1995002397A1 (en) 1993-07-14 1994-07-14 Self-assembling polynucleotide delivery system comprising dendrimer polycations

Publications (1)

Publication Number Publication Date
ATE258434T1 true ATE258434T1 (de) 2004-02-15

Family

ID=22232131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922555T ATE258434T1 (de) 1993-07-14 1994-07-14 Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält

Country Status (8)

Country Link
EP (1) EP0708637B1 (de)
JP (1) JP3785187B2 (de)
AT (1) ATE258434T1 (de)
AU (1) AU681735C (de)
CA (1) CA2163364C (de)
DE (1) DE69433519T2 (de)
ES (1) ES2211882T3 (de)
WO (1) WO1995002397A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951877B (en) * 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
WO1996019240A1 (en) * 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0874910A4 (de) * 1995-06-07 1999-04-21 Life Technologies Inc Durch peptide erhöhte kationische lipid transfektionen
CA2264012C (en) 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery
FR2754828B1 (fr) * 1996-10-23 1998-12-24 Univ Toulouse Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2761691B1 (fr) 1997-04-03 1999-05-14 Oreal Polymeres a fonction terminale thiol
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
JP2002515932A (ja) 1997-04-18 2002-05-28 カリフォルニア インスティチュート オブ テクノロジー 多機能性ポリマー性組織コーティング
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
FR2785293B1 (fr) 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
WO2001004135A2 (en) * 1999-07-13 2001-01-18 The Regents Of The University Of Michigan Crosslinked dna condensate compositions and gene delivery methods
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
FR2801592B1 (fr) 1999-11-25 2002-02-22 Centre Nat Rech Scient Dendrimeres phosphores et leurs applications comme agents de transfection
DE19960924C2 (de) * 1999-12-17 2002-08-01 Therapeutics Gmbh G.O.T. Amphiphile Polyamine, deren Anwendungen
WO2001074382A1 (en) 2000-03-31 2001-10-11 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
DE10016881B4 (de) 2000-04-05 2006-06-01 Qiagen Gmbh Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
FR2820434A1 (fr) * 2001-02-05 2002-08-09 Centre Nat Rech Scient Utilisation d'oligonucleotides pour ameliorer la transfection des plasmides dans les cellules, procede et kit de transfection
EP1356820A1 (de) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
DE60332277D1 (de) * 2002-11-26 2010-06-02 Univ Massachusetts Verabreichung von sirnas
EA200501260A1 (ru) * 2003-02-13 2006-06-30 Нэйшнел Сентер Фо Сайнтифик Рисёч "Демокритос" Многофункциональные дендримеры и сверхразветвленные полимеры и их применение в качестве систем для доставки лекарств и генетического материала
EP2287341B1 (de) 2003-12-01 2013-02-13 Life Technologies Corporation Rekombinationsstellen enthaltende Nukleinsäuremoleküle und Verfahren zur Verwendung davon
WO2006118547A1 (en) 2005-04-29 2006-11-09 Agency For Science, Technology And Research Hyperbranched polymers and their applications
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
EP2363494A1 (de) 2007-11-22 2011-09-07 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
ES2548987T3 (es) 2009-03-27 2015-10-22 Christine Chomienne Ácido nucleico antisentido de kanamicina para el tratamiento del cáncer
WO2011115555A1 (en) * 2010-03-16 2011-09-22 Ge Healthcare Bio-Sciences Ab System for improved delivery of gene modulating compounds
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
RU2771605C2 (ru) * 2020-10-26 2022-05-06 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Пептиды для внутриклеточной доставки нуклеиновых кислот
CN112807444B (zh) * 2021-01-18 2023-12-12 北京大学深圳研究生院 一种纳米抗体药物偶联物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236473A3 (de) * 1992-04-03 2003-01-15 The Regents Of The University Of California Selbst zusammenbaubares system zur verabreichung von polynukleotiden
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery

Also Published As

Publication number Publication date
JP3785187B2 (ja) 2006-06-14
ES2211882T3 (es) 2004-07-16
EP0708637A4 (de) 1998-08-12
EP0708637B1 (de) 2004-01-28
DE69433519T2 (de) 2004-11-11
CA2163364A1 (en) 1995-01-26
DE69433519D1 (de) 2004-03-04
WO1995002397A1 (en) 1995-01-26
AU681735B2 (en) 1997-09-04
EP0708637A1 (de) 1996-05-01
CA2163364C (en) 2009-10-27
AU1240095A (en) 1995-02-13
JPH09500136A (ja) 1997-01-07
AU681735C (en) 2002-02-21

Similar Documents

Publication Publication Date Title
ATE258434T1 (de) Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält
EP1236473A3 (de) Selbst zusammenbaubares system zur verabreichung von polynukleotiden
NZ306653A (en) Isolated dna il-17 receptors
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
DE69229476T2 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
TR200000015T2 (tr) Bileşikler ve metodlar
FI963103A (fi) Ei-virusvektori
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
MX9603532A (es) Sistema de suministro de acido nucleico, metodo de sintesis y sus usos.
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
JP2001506668A5 (de)
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
IL85961A (en) Leukemia-inhibitory factor, its purification and production, dna which encodes it, cells transformed by said dna and pharmaceutical compositions containing said factor
ATE47155T1 (de) Monoklonaler antikoerper.
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
AU3272395A (en) Cloning and regulation of an endothelial cell protein c/activated protein c receptor
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
BG103286A (en) Compositions and methods for ore dressing
AU6821687A (en) System for delivering drug with enhanced bioacceptability
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
ATE200518T1 (de) Hydroxyprolin reiche proteine und sie enthaltende pharmazeutische und kosmetische zubereitungen
NO870614D0 (no) Rask dna-paavisning av mikrober.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties